Owen Mumford wins Distinction in Red Dot Award (Product Design 2023) for Aidaptus® Auto-injector

Designed, developed, and manufactured by Owen Mumford, Aidaptus is a single-use auto-injector made for delivering a broad range of drugs and biologics that need subcutaneous injection. Aidaptus has unique design features that benefit both pharmaceutical companies and patients, helping it win this recognition. Its exclusive auto-adjust stopper sensing technology uses a self-adjusting plunger that automatically fits different syringe fill levels, without needing any extra components. The flexible design also works with both 1 mL and 2.25 mL prefilled glass syringes with the same compact base device. This gives pharmaceutical companies one solution to deliver multiple drug formulas. Plus, its compact build and easy two-step injection process make it user-friendly and boost confidence for patients needing subcutaneous medicine. The intuitive design supports patients in managing their treatments at home, helping to lessen demands on healthcare professionals and services.

“Red Dot is among the world’s most respected design competitions and is highly competitive, so we are honored to be recognized worldwide with distinction in the Product Design 2023 category,” said Jarl Severn, CEO Owen Mumford. “We’ve previously received this recognition for our Unifine® Pentips® Plus pen needle, and today’s news underscores our dedication and ongoing commitment to excellence in design.”

The Red Dot award has been honoring outstanding design for over 60 years. With nearly 20,000 entries every year, the Red Dot Design Award is one of the largest design competitions in the world. Each year, over 40 international expert judges select top designs from a wide array of products. The “Red Dot” has become internationally known as one of the most sought-after markers of good design quality.

“Our Aidaptus auto-injector platform is designed to make things simpler and offer a flexible solution for pharmaceutical and biotech companies working on different subcutaneous drug formulas. It addresses the challenges of changing drug formulations or delivered volumes, which helps reduce risks during drug development and lifecycle management,” said Michael Earl, Director, Owen Mumford Pharmaceutical Services. “Aidaptus will also help patients self-administer their individual therapies for diseases like rheumatoid arthritis, Crohn’s disease, and multiple sclerosis, using an easy and straightforward device.”

Aidaptus will be produced in state-of-the-art facilities in Malaysia and at Owen Mumford’s new production site in Witney, UK, which is expected to be completed later this year. The facility is being built according to BREEAM guidelines, supporting top environmental, social, and economic sustainability standards. This new center of excellence will support the company’s core values of conducting business responsibly and ethically. Furthermore, Owen Mumford is teaming up with Stevanato Group for molding and assembling Aidaptus, giving customers the advantage of dual sourcing and supply security.

For more information about the new OMPS Aidaptus® auto-injector platform, click here.

About Owen Mumford

Owen Mumford is a medical device manufacturer with a large international presence in the UK, Europe, US, and Asia, leading medical technology advancements for 70 years. The company makes its own line of medical products and is a trusted partner to some of the world’s top pharmaceutical and diagnostic companies. Its top medication delivery, blood-sampling, and testing solutions are created with patient, healthcare professional, and caregiver comfort, safety, and dignity as the priority. Guided by its commitment to doing business the right way, Owen Mumford is one of the first medical device companies globally to earn B Corp certification and has set science-based goals to reach net zero by 2045 as part of its long-standing and always-improving sustainability mission.